A 28-year-old nulliparous woman with severe menorrhagia unresponsive to 3 months of combined oral contraceptive therapy (norethisterone 5 mg daily during menses) presents with Hb 8.2 g/dL. Transvaginal ultrasound shows a 3 cm submucosal fibroid (FIGO type 2) with normal adenomyosis. She desires fertility preservation. What is the next step in management?

## Management of Submucosal Fibroid with Fertility Desire **Key Point:** In a nulliparous woman with a submucosal fibroid causing menorrhagia refractory to medical therapy, preoperative GnRH agonist therapy followed by hysteroscopic myomectomy is the evidence-based approach to optimize surgical outcomes and preserve fertility. ### Why GnRH Agonist Pretreatment? GnRH agonists (leuprolide, goserelin) induce hypoestrogenaemia, which: 1. **Reduces fibroid volume** by 30–50% within 3 months 2. **Decreases uterine vascularity**, reducing intraoperative bleeding 3. **Thins the endometrium**, improving visualization during hysteroscopy 4. **Increases hemoglobin** preoperatively, reducing transfusion risk 5. **Improves surgical success rates** and reduces recurrence ### FIGO Classification of Submucosal Fibroids | FIGO Type | Myometrial Invasion | Hysteroscopic Feasibility | Management | |-----------|-------------------|--------------------------|-------------| | 0 | None (pedunculated) | Easy | Hysteroscopic resection | | 1 | <50% | Moderate | Hysteroscopic ± GnRH pretreatment | | 2 | ≥50% | Difficult | **GnRH pretreatment + hysteroscopic resection** | | 3 | None (intramural) | Not suitable | Myomectomy (open/laparoscopic) | **Clinical Pearl:** Type 2 fibroids (≥50% myometrial invasion) have higher rates of incomplete resection and uterine perforation without GnRH pretreatment. Pretreatment reduces these complications significantly. ### Management Algorithm for Submucosal Fibroid ```mermaid flowchart TD A[Submucosal Fibroid + Menorrhagia]:::outcome --> B{FIGO Type?}:::decision B -->|Type 0-1| C[Hysteroscopic Myomectomy]:::action B -->|Type 2| D[GnRH Agonist 3 months]:::action D --> E[Hysteroscopic Myomectomy]:::action B -->|Type 3| F[Myomectomy: Open/Laparoscopic]:::action A --> G{Fertility Desired?}:::decision G -->|No| H[Hysterectomy Option]:::action G -->|Yes| I[Fertility-Sparing Surgery]:::action ``` **High-Yield:** **GnRH agonist + hysteroscopic myomectomy** is the gold standard for Type 2 submucosal fibroids in women desiring fertility. Duration: 3 months preoperatively. **Mnemonic:** **GnRH-HYS** = GnRH agonist → Hysteroscopic myomectomy for submucosal fibroids (especially Type 2). ### Why Other Options Are Suboptimal - **Hysteroscopic myomectomy alone** (without GnRH pretreatment) in Type 2 fibroids: Higher failure rate, incomplete resection, and uterine perforation risk. - **Hysterectomy**: Eliminates fertility; reserved for completed childbearing or failed conservative surgery. - **Uterine artery embolization**: Non-surgical option but associated with ovarian dysfunction and reduced fertility; not first-line in nulliparous women. [cite:RCOG Green-top Guideline 44 (Heavy Menstrual Bleeding); FIGO Classification of Submucosal Fibroids]